{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:14:32Z","timestamp":1784128472638,"version":"3.55.0"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Although the prognosis of patients with hematologic cancers has improved significantly owing to the advance of radiotherapy, chemotherapy, targeted therapies, immunotherapies, and hematopoietic stem cell transplantation therapy, disease relapse and refractory are still very prevalent and remain the major obstacles for long-term patient survival. Recent evidence suggests that drug-tolerant persister (DTP) cells are considered to be the cellular reservoir for tumor relapses and drug resistance formation. DTP cells refer to tumor cells that are acquired tolerance to anticancer drugs during exposure. Distinct from genetic mutations which cause stable drug-resistance, drug-tolerance in DTP cells is reversible which is primarily mediated by non-genetic alterations including changes in epigenetic modification, metabolic reprogramming, and\/or transcriptional regulation. However, under prolonged or repeat drug-exposure, DTP cells acquire mutations in genes that are required for drug-treatment response and become stable drug-resistance. Targeting stable drug-resistant cell therapy is very challenge which needs novel drugs. Thus, targeted DTP cells therapy is particularly interesting which only needs to inhibit the essential adaptive pathways to prevent DTP cells formation or restore drug-sensitivity to DTP cells. During the past 15 years, significant efforts have been made to understand the mechanisms that drive the generation of DTP cells and define unique vulnerabilities that can be exploited for targeting DTP cells therapies. Combination of drug with adaptive pathway inhibitors has been attempted to prevent recurrence and refractory for durable treatment efficacy. Here, we review the advances of DTP cells research in hematologic cancers and summarize the phenotypic and functional characterizations of DTP cells defined in different research models. By deliberating the mechanisms of DTP cells generation and evolution, we discuss the potential therapeutic strategies of targeting DTP cells for more an effective treatment of hematological malignancies.<\/jats:p>","DOI":"10.3389\/fphar.2026.1740281","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:01:16Z","timestamp":1776164476000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug-tolerant persister cells: the deadly survivors in hematological malignancies"],"prefix":"10.3389","volume":"17","author":[{"given":"Qianying","family":"Ma","sequence":"first","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyong","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanxia","family":"Zhou","sequence":"additional","affiliation":[{"name":"Gansu Provincial Clinical Medical Research Center for Molecular Diagnosis and Treatment of Hematological Diseases, The First Hospital of Lanzhou University","place":["Lanzhou, China"]},{"name":"The Laboratory Center, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Cheng","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University","place":["Lanzhou, China"]},{"name":"Department of Hematology, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University","place":["Lanzhou, China"]},{"name":"Gansu Provincial Clinical Medical Research Center for Molecular Diagnosis and Treatment of Hematological Diseases, The First Hospital of Lanzhou University","place":["Lanzhou, China"]},{"name":"The Laboratory Center, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"B3","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1080\/10428194.2020.1789630","article-title":"Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"61","author":"Ali","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"B5","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/cancers14040976","article-title":"Dissecting Tumor growth: the role of cancer stem cells in drug resistance and recurrence","volume":"14","author":"Aramini","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1038\/s41467-018-05626-2","article-title":"Notch3-dependent beta-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC","volume":"9","author":"Arasada","year":"2018","journal-title":"Nat. Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.3390\/ijms21176091","article-title":"Drug resistance in hematological malignancies","volume":"21","author":"Auberger","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12929-018-0426-4","article-title":"Cancer stem cells as key drivers of tumour progression","volume":"25","author":"Ayob","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1016\/s2352-3026(24)00034-6","article-title":"Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial","volume":"11","author":"Bazinet","year":"2024","journal-title":"Lancet Haematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1038\/s41467-019-10652-9","article-title":"Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia","volume":"10","author":"Bell","year":"2019","journal-title":"Nat. Commun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","article-title":"Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma","volume":"66","author":"Bollard","year":"2017","journal-title":"Gut"},{"key":"B14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41419-024-06674-x","article-title":"ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC","volume":"15","author":"B\u00f6pple","year":"2024","journal-title":"Cell Death Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biocel.2018.12.001","article-title":"Breast cancer stem cells: biology and therapeutic implications","volume":"107","author":"Butti","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.trecan.2023.09.003","article-title":"Non-genetic mechanisms of drug resistance in acute leukemias","volume":"10","author":"Calderon","year":"2024","journal-title":"Trends Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41375-021-01341-y","article-title":"Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics","volume":"36","author":"Candelli","year":"2022","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1023\/a:1008389706725","article-title":"Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance","volume":"12","author":"Cara","year":"2001","journal-title":"Ann. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.Cd-20-1265","article-title":"Ontogeny and vulnerabilities of drug-tolerant persisters in HER2+ breast cancer","volume":"12","author":"Chang","year":"2022","journal-title":"Cancer Discov."},{"key":"B20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3760\/cma.j.issn.0253-2727.2019.01.017","article-title":"The aberrant epigenetic regulation and epigenomic landscape alteration in human acute myelogenous leukemia and the emerged agents that target epigenetic regulators","volume":"40","author":"Chen","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov."},{"key":"B23","doi-asserted-by":"publisher","first-page":"105017","DOI":"10.1016\/j.isci.2022.105017","article-title":"Heterotypic cell-in-cell structures between cancer and NK cells are associated with enhanced anticancer drug resistance","volume":"25","author":"Choe","year":"2022","journal-title":"iScience"},{"key":"B148","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1146\/annurev-cancerbio-070924-120742","article-title":"Targeting minimal residual disease","volume":"9","author":"Chou","year":"2025","journal-title":"Annu. Rev. Cancer Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nm.2304","article-title":"The cancer stem cell: premises, promises and challenges","volume":"17","author":"Clevers","year":"2011","journal-title":"Nat. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","article-title":"Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing","volume":"27","author":"Cohen","year":"2021","journal-title":"Nat. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/biom13060897","article-title":"The role of extracellular vesicles in the pathogenesis of hematological malignancies: interaction with tumor microenvironment; a potential biomarker and targeted therapy","volume":"13","author":"Das","year":"2023","journal-title":"Biomolecules"},{"key":"B28","doi-asserted-by":"publisher","first-page":"103235","DOI":"10.1016\/j.ebiom.2021.103235","article-title":"Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia","volume":"64","author":"de Groot","year":"2021","journal-title":"EBioMedicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1182\/bloodadvances.2023012298","article-title":"Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies","volume":"8","author":"Deng","year":"2024","journal-title":"Blood Adv."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1158\/0008-5472.Can-21-3844","article-title":"Drug-Tolerant persister cells in cancer therapy resistance","volume":"82","author":"Dhanyamraju","year":"2022","journal-title":"Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1038\/s41467-017-01834-4","article-title":"The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia","volume":"8","author":"Di Tullio","year":"2017","journal-title":"Nat. Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/s0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"B142","doi-asserted-by":"publisher","first-page":"6598","DOI":"10.1038\/s44318-025-00602-1","article-title":"H2BK120ub and its reader RNF169 sequentially regulate replication fork remodeling and stability","volume":"44","author":"Duzanic","year":"2025","journal-title":"Embo. j."},{"key":"B35","doi-asserted-by":"publisher","first-page":"eaav0936","DOI":"10.1126\/scitranslmed.aav0936","article-title":"Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state","volume":"11","author":"Echeverria","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.Cd-16-0441","article-title":"Chemotherapy-Resistant human acute Myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"key":"B37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/0008-5472.can-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13046-019-1505-4","article-title":"A pre-existing population of ZEB2(+) quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer","volume":"39","author":"Francescangeli","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.molcel.2012.05.023","article-title":"RNF20 and USP44 regulate stem cell differentiation by modulating H2B monoubiquitylation","volume":"46","author":"Fuchs","year":"2012","journal-title":"Mol. Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41408-025-01270-4","article-title":"Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days","volume":"15","author":"Gangat","year":"2025","journal-title":"Blood Cancer J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/cas.14351","article-title":"Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia","volume":"111","author":"Ge","year":"2020","journal-title":"Cancer Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41416-020-01191-y","article-title":"Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance","volume":"124","author":"Ge","year":"","journal-title":"Br. J. Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1111\/cas.14892","article-title":"Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia","volume":"112","author":"Ge","year":"","journal-title":"Cancer Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood.2019003124","article-title":"Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia","volume":"136","author":"Gebru","year":"2020","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1167443","DOI":"10.3389\/fimmu.2023.1167443","article-title":"V\u03b39V\u03b42 T-cell immunotherapy in blood cancers: ready for prime time?","volume":"14","author":"Giannotta","year":"2023","journal-title":"Front. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fgene.2019.00133","article-title":"Epigenetic modifications in Acute Myeloid leukemia: Prognosis, treatment, and heterogeneity","volume":"10","author":"Goldman","year":"2019","journal-title":"Front. Genet."},{"key":"B48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nm.4247","article-title":"Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia","volume":"23","author":"Gollner","year":"2017","journal-title":"Nat. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.3324\/haematol.2024.287119","article-title":"Measurable residual disease recurrence as early warning of relapse in acute myeloid leukemia","volume":"110","author":"Gong","year":"2025","journal-title":"Haematologica"},{"key":"B50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2017.07.002","article-title":"Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure","volume":"32","author":"Guler","year":"2017","journal-title":"Cancer Cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","article-title":"Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer","volume":"15","author":"Haderk","year":"2024","journal-title":"Nat. Commun."},{"key":"B52","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","article-title":"Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ijc.34243","article-title":"Therapy resistance mechanisms in hematological malignancies","volume":"152","author":"Hofmann","year":"2023","journal-title":"Int. J. Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"8721","DOI":"10.7150\/thno.41648","article-title":"Stem cell programs in cancer initiation, progression, and therapy resistance","volume":"10","author":"Huang","year":"2020","journal-title":"Theranostics"},{"key":"B152","doi-asserted-by":"publisher","first-page":"7190","DOI":"10.1074\/jbc.M110.158311","article-title":"Regulation of histone H2A and H2B deubiquitination and Xenopus development by USP12 and USP46","volume":"286","author":"Joo","year":"2011","journal-title":"J Biol Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1016\/j.cell.2022.07.025","article-title":"Sublethal cytochrome c release generates drug-tolerant persister cells","volume":"185","author":"Kalkavan","year":"2022","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.molcel.2005.11.012","article-title":"The human homolog of yeast BRE1 functions as a transcriptional coactivator through direct activator interactions","volume":"20","author":"Kim","year":"2005","journal-title":"Mol. Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1182\/blood-2024-202733","article-title":"ATR inhibitor Elimusertib suppresses drug persister clones in TP53-Mutated acute Myeloid leukemia via CGAS-Sting-Mediated cell death","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/ng.2913","article-title":"An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia","volume":"46","author":"Knoechel","year":"2014","journal-title":"Nat. Genet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"801632","DOI":"10.3389\/fmed.2022.801632","article-title":"Maintenance with hypomethylating agents after allogeneic stem cell transplantation in Acute Myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis","volume":"9","author":"Kungwankiattichai","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/annonc\/mdh006","article-title":"Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance","volume":"15","author":"Kurata","year":"2004","journal-title":"Ann. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-Induced Tumor dormancy through YAP-Mediated transcriptional reprogramming of the apoptotic pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/13543784.2019.1678583","article-title":"Cyclin-dependent kinase (CDK) 9 and 4\/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach","volume":"28","author":"Lee","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1586552","DOI":"10.3389\/fmed.2025.1586552","article-title":"Drug-tolerant persister cells in acute myeloid leukemia: pressing challenge and promising new strategies for treatment","volume":"12","author":"Li","year":"2025","journal-title":"Front. Med. (Lausanne)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00432-018-2631-7","article-title":"Therapeutic potential of GSK-J4, a histone demethylase KDM6B\/JMJD3 inhibitor, for acute myeloid leukemia","volume":"144","author":"Li","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/0008-5472.Can-22-2370","article-title":"PINK1-Mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s13287-024-04061-z","article-title":"Exosome crosstalk between cancer stem cells and tumor microenvironment: cancer progression and therapeutic strategies","volume":"15","author":"Li","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","article-title":"Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance","volume":"20","author":"Liau","year":"2017","journal-title":"Cell Stem Cell"},{"key":"B71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccr.2014.03.008","article-title":"Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4","volume":"25","author":"Liu","year":"2014","journal-title":"Cancer Cell"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat. Genet."},{"key":"B74","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12943-025-02323-9","article-title":"Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2015-10-662684","article-title":"Introduction to the review series on advances in acute myeloid leukemia (AML)","volume":"127","author":"L\u00f6wenberg","year":"2016","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0841","article-title":"Targeting the MTF2-MDM2 axis sensitizes Refractory acute Myeloid leukemia to chemotherapy","volume":"8","author":"Maganti","year":"2018","journal-title":"Cancer Discov."},{"key":"B77","doi-asserted-by":"publisher","first-page":"165339","DOI":"10.1016\/j.bbadis.2018.11.015","article-title":"Cancer stem cells: road to therapeutic resistance and strategies to overcome resistance","volume":"1866","author":"Makena","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13059-024-03260-4","article-title":"Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia","volume":"25","author":"Malyukova","year":"2024","journal-title":"Genome Biol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tem.2023.11.005","article-title":"Metabolic challengers selecting tumor-persistent cells","volume":"35","author":"Mancini","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"B80","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/stcltm\/szab029","article-title":"The influence of cancer stem cells on the risk of relapse in adenocarcinoma and squamous cell carcinoma of the lung: a prospective cohort Study","volume":"11","author":"Masciale","year":"2022","journal-title":"Stem Cells Transl. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1080\/15592294.2019.1640546","article-title":"Epidrugs: targeting epigenetic marks in cancer treatment","volume":"14","author":"Miranda Furtado","year":"2019","journal-title":"Epigenetics"},{"key":"B84","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2022.12.003","article-title":"Single-Cell analysis reveals transcriptomic features of drug-tolerant persisters and stromal adaptation in a patient-derived EGFR-Mutated lung adenocarcinoma Xenograft model","volume":"18","author":"Moghal","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"23891","DOI":"10.1073\/pnas.1915108116","article-title":"WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1-and S-phase cells","volume":"116","author":"Moiseeva","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B86","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3324\/haematol.2024.286018","article-title":"Acute myeloid leukemia drug-tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing","volume":"110","author":"Morgenstern","year":"2025","journal-title":"Haematologica"},{"key":"B87","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012615-044438","article-title":"Cancer stem cells: basic concepts and therapeutic implications","volume":"11","author":"Nassar","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e93019","DOI":"10.7554\/eLife.93019","article-title":"Convergent epigenetic evolution drives relapse in acute myeloid leukemia","volume":"13","author":"Nuno","year":"2024","journal-title":"Elife"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2024.08.22.609211","DOI":"10.1101\/2024.08.22.609211","article-title":"Remodelling of the glycome of B-cell precursor acute lymphoblastic leukemia cells developing drug-tolerance","author":"Oliveira","year":"2024","journal-title":"bioRxiv"},{"key":"B90","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","article-title":"Cycling cancer persister cells arise from lineages with distinct programs","volume":"596","author":"Oren","year":"2021","journal-title":"Nature"},{"key":"B91","doi-asserted-by":"publisher","first-page":"S205","DOI":"10.3816\/CLM.2009.s.013","article-title":"Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia","volume":"9","author":"Palomero","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"B92","doi-asserted-by":"publisher","first-page":"156036","DOI":"10.1016\/j.prp.2025.156036","article-title":"B-cell lymphoma: advances in pathogenesis, diagnosis, and targeted therapies","volume":"271","author":"Patil","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"B93","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11899-009-0023-4","article-title":"Infant acute lymphoblastic leukemia: lessons learned and future directions","volume":"4","author":"Pieters","year":"2009","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B94","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","article-title":"Drug-tolerant persister cells in cancer: the cutting edges and future directions","volume":"20","author":"Pu","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1158\/0008-5472.Can-13-3456","article-title":"The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation","volume":"74","author":"Raha","year":"2014","journal-title":"Cancer Res."},{"key":"B147","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.7150\/thno.42523","article-title":"Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer","volume":"10","author":"Ravindran Menon","year":"2020","journal-title":"Theranostics"},{"key":"B96","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.tips.2018.12.004","article-title":"Targeting cancer cell dormancy","volume":"40","author":"Recasens","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","article-title":"Colorectal cancer cells enter a diapause-like DTP State to survive chemotherapy","volume":"184","author":"Rehman","year":"2021","journal-title":"Cell"},{"key":"B98","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1038\/s41467-018-05729-w","article-title":"Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer","volume":"9","author":"Risom","year":"2018","journal-title":"Nat. Commun."},{"key":"B100","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1158\/2159-8290.CD-17-0461","article-title":"Suppression of adaptive responses to targeted cancer therapy by transcriptional repression","volume":"8","author":"Rusan","year":"2018","journal-title":"Cancer Discov."},{"key":"B101","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nbt.1607","article-title":"Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML","volume":"28","author":"Saito","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.stem.2024.06.003","article-title":"Cancer stem cell mimicry for immune evasion and therapeutic resistance","volume":"31","author":"Saw","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B105","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","first-page":"108421","DOI":"10.1016\/j.celrep.2020.108421","article-title":"Melanoma persister cells are tolerant to BRAF\/MEK inhibitors via ACOX1-Mediated fatty acid oxidation","volume":"33","author":"Shen","year":"2020","journal-title":"Cell Rep."},{"key":"B108","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/cancers11050732","article-title":"Targeting cancer stem cells: a strategy for effective eradication of cancer","volume":"11","author":"Shibata","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B109","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1158\/0008-5472.Can-20-0378","article-title":"Slow-Cycling cancer stem cells regulate progression and chemoresistance in Colon cancer","volume":"80","author":"Shiokawa","year":"2020","journal-title":"Cancer Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"key":"B145","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13148-025-01966-1","article-title":"The synergistic action of HDAC inhibitor with cisplatin impedes survival and proliferation of drug-tolerant persister in gastric and liver cancer cells","volume":"17","author":"Singh","year":"2025","journal-title":"Clin. Epigenetics"},{"key":"B111","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.3324\/haematol.2023.283494","article-title":"B-cell precursor acute lymphoblastic leukemia elicits an interferon-\u03b1\/\u03b2 response in bone marrow-derived mesenchymal stroma","volume":"109","author":"Smeets","year":"2024","journal-title":"Haematologica"},{"key":"B113","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"B146","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41375-024-02363-y","article-title":"Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14)","volume":"39","author":"Tang","year":"2025","journal-title":"Leukemia"},{"key":"B115","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"key":"B116","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/ijms22031026","article-title":"Gut Microbiota influence in hematological malignancies: from Genesis to cure","volume":"22","author":"Uribe-Herranz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B119","doi-asserted-by":"publisher","first-page":"105013","DOI":"10.1016\/j.isci.2022.105013","article-title":"Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters","volume":"25","author":"van Gils","year":"2022","journal-title":"iScience"},{"key":"B120","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nchembio.2085","article-title":"An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells","volume":"12","author":"Vinogradova","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/nhh.0000000000001249","article-title":"Multiple myeloma","volume":"42","author":"Vrtis","year":"2024","journal-title":"Home Healthc. Now."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","article-title":"Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies","volume":"11","author":"Walcher","year":"2020","journal-title":"Front. Immunol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tcb.2024.06.001","article-title":"Roles of H3K4 methylation in biology and disease","volume":"35","author":"Wang","year":"2025","journal-title":"Trends Cell Biol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"e2304939","DOI":"10.1002\/advs.202304939","article-title":"Identification of PRDX5 as A target for the treatment of castration-resistant prostate cancer","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"B125","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41416-025-02947-0","article-title":"Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study","volume":"132","author":"Wang","year":"2025","journal-title":"Br. J. Cancer"},{"key":"B127","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"B128","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/pbc.25470","article-title":"Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: children's Oncology Group Study AALL0434","volume":"62","author":"Winter","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"B149","doi-asserted-by":"publisher","first-page":"115110","DOI":"10.1016\/j.bcp.2022.115110","article-title":"Epigenetic regulation of cancer stem cells: shedding light on the refractory\/relapsed cancers","volume":"202","author":"Xu","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"105036","DOI":"10.1016\/j.critrevonc.2025.105036","article-title":"Targeting drug-tolerant persister cells to overcome resistance in HER2-positive gastric cancer","volume":"217","author":"Xu","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"218067","DOI":"10.1016\/j.canlet.2025.218067","article-title":"Exploiting metabolic vulnerabilities in cancer: from mechanisms to therapeutic opportunities","volume":"634","author":"Xue","year":"2025","journal-title":"Cancer Lett."},{"key":"B131","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"key":"B141","doi-asserted-by":"publisher","first-page":"122581","DOI":"10.1016\/j.biomaterials.2024.122581","article-title":"Hierarchical self-recognition and response in CSC and non-CSC micro-niches for cancer therapy","volume":"308","author":"Yang","year":"2024","journal-title":"Biomaterials"},{"key":"B132","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3727\/096504005775082020","article-title":"Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases","volume":"15","author":"Yano","year":"2005","journal-title":"Oncol. Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1182\/blood-2024-204209","article-title":"Combinatorial therapy of CDK9 inhibitor with CD19 CAR-T to reciprocally overcome therapy resistance and enhance treatment efficacies against aggressive B-Cell lymphomas","volume":"144","author":"Yin","year":"2024","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.molcel.2007.12.015","article-title":"The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression","volume":"29","author":"Zhang","year":"2008","journal-title":"Mol. Cell"},{"key":"B135","doi-asserted-by":"publisher","first-page":"913669","DOI":"10.3389\/fonc.2022.913669","article-title":"Glutathione peroxidase 4 as a therapeutic target for anti-colorectal cancer drug-tolerant persister cells","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"2023.02.28.530540","DOI":"10.1101\/2023.02.28.530540","article-title":"Drug-tolerant persister B-cell precursor acute lymphoblastic leukemia cells","author":"Zhang","year":"2023","journal-title":"bioRxiv"},{"key":"B137","doi-asserted-by":"publisher","first-page":"103494","DOI":"10.1016\/j.jtho.2025.10.001","article-title":"GSTA1 conferred tolerance to osimertinib and provided strategies to overcome drug-tolerant persister in EGFR-Mutant lung adenocarcinoma","volume":"21","author":"Zhang","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e06950","DOI":"10.1002\/advs.202506950","article-title":"EGFR-TKIs induced DPP4 drives metabolic reprogramming of persister cells in lung cancer","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"B139","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ccell.2019.04.005","article-title":"BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models","volume":"35","author":"Zhao","year":"2019","journal-title":"Cancer Cell"},{"key":"B140","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.molcel.2005.09.025","article-title":"Monoubiquitination of human histone H2B: the factors involved and their roles in HOX gene regulation","volume":"20","author":"Zhu","year":"2005","journal-title":"Mol. Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1740281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:01:19Z","timestamp":1776164479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1740281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":136,"alternative-id":["10.3389\/fphar.2026.1740281"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1740281","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1740281"}}